Product Description
treatment of neuropathic pain in patients with cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00474916)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: DARA BioSciences|Midatech Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Neuralgia|Neuropathic Pain
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00017238 |
NCI-2012-03132 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2008-11-01 |
2020-10-26 |
Primary Endpoints |
|
NCT00002923 |
NSC650426 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2000-01-01 |
2019-03-21 |
||
NCT00474916 |
DTCL100 | P2 |
Completed |
Neuropathic Pain|Neuralgia |
2009-03-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/28/2022 |
News Article |
Global Pain Therapeutics Market to 2029 - Featuring Abbott Laboratories, AstraZeneca and GlaxoSmithKline Among Others |